Prolia vs. Reclast
See how Prolia and Reclast compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Prolia is a twice-yearly injection while Reclast is typically a once-yearly infusion (or once every two years for prevention), so the drugs differ mainly in how often treatment is needed.
Prolia covers a wider range of uses, including bone loss from cancer hormone therapies, while Reclast is the only one of the two approved for Paget's disease of bone.
Stopping Prolia without switching to another antiresorptive can cause rebound vertebral fractures, while Reclast's bone-bound effect tapers off gradually after the last dose.
Prolia vs. Reclast Drug Summary
Prolia
Prolia (denosumab) is a RANK ligand inhibitor given as a subcutaneous injection by a healthcare provider once every six months. It is approved to treat osteoporosis in postmenopausal women, men, and people at high fracture risk from long-term steroid use or certain cancer hormone therapies.
Reclast
Reclast (zoledronic acid) is a bisphosphonate given as an intravenous infusion, typically once a year for osteoporosis treatment or once every two years for prevention. It is also approved to treat glucocorticoid-induced osteoporosis and Paget's disease of bone.
Prolia vs. Reclast Side Effects
Prolia
Reclast
Prolia vs. Reclast Dosage
Prolia
Reclast
| STAGE | DOSE | WHEN |
| Starting dose | 60 mg every 6 months | At the start |
| Maximum dose | 60 mg every 6 months | Same as starting |
| Dose changes | None | Fixed dose |
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg IV infusion | At the start |
| Maximum dose | 5 mg IV infusion | Same as starting |
| Dose changes | None | Fixed dose |
Prolia
| STAGE | DOSE | WHEN |
| Starting dose | 60 mg every 6 months | At the start |
| Maximum dose | 60 mg every 6 months | Same as starting |
| Dose changes | None | Fixed dose |
Reclast
| STAGE | DOSE | WHEN |
| Starting dose | 5 mg IV infusion | At the start |
| Maximum dose | 5 mg IV infusion | Same as starting |
| Dose changes | None | Fixed dose |
Prolia vs. Reclast Indications
Prolia
Prolia treats osteoporosis by blocking RANK ligand, a protein involved in bone breakdown, and is given as an injection every six months. Its FDA approval covers a wide range of high-fracture-risk groups, including people losing bone density from cancer treatment.
Postmenopausal women with osteoporosis at high fracture risk
Men with osteoporosis at high fracture risk
Glucocorticoid-induced osteoporosis in men and women
Bone loss from androgen deprivation therapy in prostate cancer
Bone loss from aromatase inhibitor therapy in breast cancer
Reclast
Reclast treats osteoporosis with a bisphosphonate infusion given once a year, or once every two years to prevent postmenopausal osteoporosis. Its approval also extends to Paget's disease of bone, a use Prolia does not share.
Treatment of postmenopausal osteoporosis
Prevention of postmenopausal osteoporosis
Osteoporosis in men
Treatment and prevention of glucocorticoid-induced osteoporosis
Paget's disease of bone
Prolia vs. Reclast Pros and Cons
Prolia
Prolia's twice-yearly injection and broad label, including bone loss from cancer hormone therapy, offer flexibility, but stopping it without follow-up therapy can trigger rebound vertebral fractures. It also carries a boxed warning for hypocalcemia in advanced kidney disease.
Pros
Approved for bone loss caused by aromatase inhibitors and androgen deprivation therapy
Quick subcutaneous injection, no IV line or infusion time needed
No routine pre-dose hydration or renal clearance check required
Fewer patients report flu-like acute-phase symptoms than with Reclast
Cons
Must be dosed exactly every 6 months to avoid gaps in protection
Stopping without a follow-up antiresorptive can cause rebound vertebral fractures
Carries a boxed warning for severe hypocalcemia in advanced kidney disease
Not approved for Paget's disease of bone
Reclast
Reclast's once-yearly, or less frequent, infusion covers standard osteoporosis care and Paget's disease, but it commonly causes flu-like symptoms in the days following infusion and is not recommended for patients with significant kidney impairment.
Pros
Dosed only once a year for treatment, or once every 2 years for prevention
Also FDA-approved for Paget's disease of bone
Effects taper gradually after stopping, without the rebound fracture risk seen with Prolia
No boxed warning for hypocalcemia; risk is managed with pre-treatment calcium correction
Cons
Common flu-like acute-phase reaction (fever, myalgia, arthralgia) after infusion
Requires a 15-plus minute IV infusion visit rather than a quick injection
Contraindicated in patients with significant kidney impairment (CrCl under 35 mL/min)
Not approved for bone loss from cancer hormone therapies
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.